Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) had its price objective increased by equities research analysts at The Goldman Sachs Group from $5.50 to $7.50 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price target suggests a potential downside of 2.72% from the stock’s previous close.
Several other research firms have also recently issued reports on ADPT. Piper Sandler increased their price target on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. BTIG Research lifted their target price on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th.
Get Our Latest Stock Report on Adaptive Biotechnologies
Adaptive Biotechnologies Stock Down 1.8 %
Institutional Investors Weigh In On Adaptive Biotechnologies
Several hedge funds have recently modified their holdings of ADPT. China Universal Asset Management Co. Ltd. raised its holdings in Adaptive Biotechnologies by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,292 shares of the company’s stock valued at $188,000 after acquiring an additional 2,928 shares during the last quarter. KBC Group NV purchased a new stake in Adaptive Biotechnologies in the 4th quarter valued at about $50,000. Impact Partnership Wealth LLC lifted its holdings in shares of Adaptive Biotechnologies by 8.8% during the 4th quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company’s stock worth $114,000 after acquiring an additional 1,539 shares during the period. SG Americas Securities LLC boosted its position in shares of Adaptive Biotechnologies by 11.7% in the fourth quarter. SG Americas Securities LLC now owns 45,944 shares of the company’s stock worth $275,000 after acquiring an additional 4,799 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new position in Adaptive Biotechnologies during the fourth quarter worth approximately $59,000. 99.17% of the stock is owned by institutional investors and hedge funds.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Featured Articles
- Five stocks we like better than Adaptive Biotechnologies
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Steel Stocks Soaring After Tariff Announcements
- Most active stocks: Dollar volume vs share volume
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.